TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04674969: Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

Sponsor: Boston Scientific Corporation · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 5000 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT04674969 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04674969 Rescue Dossier →